145726
DL-Tyrosine
99%
동의어(들):
(±)-2-Amino-3-(4-hydroxyphenyl)propionic acid, 3-(4-Hydroxyphenyl)-DL-alanine
로그인조직 및 계약 가격 보기
모든 사진(3)
About This Item
Linear Formula:
4-(HO)C6H4CH2CH(NH2)COOH
CAS Number:
Molecular Weight:
181.19
Beilstein:
515881
EC Number:
MDL number:
UNSPSC 코드:
12352209
PubChem Substance ID:
NACRES:
NA.22
추천 제품
분석
99%
양식
powder
반응 적합성
reaction type: solution phase peptide synthesis
mp
≥300 °C (lit.)
응용 분야
peptide synthesis
SMILES string
NC(Cc1ccc(O)cc1)C(O)=O
InChI
1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)
InChI key
OUYCCCASQSFEME-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
이미 열람한 고객
Shannon L Maude et al.
Blood, 125(11), 1759-1767 (2015-02-04)
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well as a high rate of induction failure. Frequent mutations in cytokine receptor and Janus kinase
W D Phillips et al.
Experimental neurology, 270, 29-40 (2014-12-30)
Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several
S P Gorantla et al.
Leukemia, 29(8), 1763-1770 (2015-03-13)
FIP1L1-PDGFRA is a constitutively activated kinase described in chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). Imatinib is clinically active in FIP1L1-PDGFRA-positive diseases. Using in vitro screening to identify imatinib-resistant mutations, we frequently detected a Phe to Ser exchange at
Philippe Menasché et al.
European heart journal, 36(12), 743-750 (2014-05-20)
There is now compelling evidence that cells committed to a cardiac lineage are most effective for improving the function of infarcted hearts. This has been confirmed by our pre-clinical studies entailing transplantation of human embryonic stem cell (hESC)-derived cardiac progenitors
Martin Schlumberger et al.
The New England journal of medicine, 372(7), 621-630 (2015-02-12)
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.